W

Wesper

At-home sleep testing platform and analytics

Overview

Wesper offers a sleep diagnostics platform that enables at-home, longitudinal sleep testing for individuals and healthcare providers. It provides sleep testing kits and a data analytics platform on a subscription basis, delivering personalized sleep data to patients and clinicians to guide treatment choices and improve adherence. The system combines home-based testing with scalable analytics to support accurate, inclusive sleep data and better clinical decisions. Wesper distinguishes itself through its focus on long-term, patient-centered data collection, at-home convenience, and partnerships with healthcare institutions to extend access and drive better outcomes. The company’s goal is to improve sleep quality and clinical outcomes by making reliable sleep diagnostics and data-driven treatment guidance more accessible.

Work here?Claim your company

About Wesper

Simplify's Rating
Why Wesper is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsHealthcare

Company Size

11-50

Company Stage

Series A

Total Funding

$16.1M

Headquarters

New York City, New York

Founded

2017

Get referred to Wesper

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared Wesper’s next-generation longitudinal device in January 2026, expanding clinical utility.
  • SLEEP 2026 launches target screening, monitoring, and follow-up, broadening addressable sleep workflows.
  • The RWJUH Somerset dropship announcement showed hospital demand for faster home sleep testing, despite the retraction.

What critics are saying

  • Wesper’s March 18, 2026 hospital capacity release was later officially disavowed, damaging credibility.
  • PPG-based Lite and respiratory HSAT face pricing pressure from WatchPAT, ResMed, and lab incumbents.
  • If Wesper cannot convert clinical validation into reimbursement and volume, its niche platform stalls.

What makes Wesper unique

  • Wesper Lab and Lite share one record, one pipeline, and seamless patient escalation in 2026.
  • Wesper’s FDA-cleared longitudinal patch captures multi-night respiratory data, not one-night snapshots.
  • The company claims 96% AHI correlation to PSG and AI central apnea detection validation.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$16.1M

Below

Industry Average

Funded Over

3 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Below Average

Industry standards

$15M
$7.5M
$8.2M
$15M
$30M

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • Remote Work Options
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Conference Attendance Budget
  • Professional Development Budget
  • Mentorship Program

Company News

Ohsem.me
Oct 15th, 2026
Wesper named to TIME's list of the Best Inventions of 2026 as A Special Mention.

Wesper named to TIME's list of the Best Inventions of 2026 as A Special Mention. 16/10/2026 TIME recognition highlights Wesper's work to make sleep testing accessible New York City, United States, October 15, 2026 - Wesper, a leader in advanced home sleep apnea testing (HSAT), has been recognized as a 2026 TIME Best Inventions Special Mention, placing the company among a select group of innovators recognized by TIME for developing products and technologies that are helping shape the future. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields - such as health care and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. For Wesper, the recognition highlights the growing importance of rethinking how sleep disorders are studied. Rather than relying solely on traditional sleep testing methods that can be difficult to use and limited to a single night, Wesper's wearable technology lets patients collect sleep data at home across multiple nights. "This recognition from TIME is meaningful because it validates the need to rethink how we approach sleep health," said Dr. Amir Reuveny, CEO and founder of Wesper. "Millions of people struggle with undiagnosed or undertreated sleep disorders, yet access to reliable, clinical-grade sleep testing remains a significant barrier. We built Wesper around the idea that even the most rigorous sleep testing should fit into people's lives, not disrupt them." Wesper's wireless wearable technology is designed to capture key sleep and breathing data without a traditional nasal cannula, helping patients test in their own beds across multiple nights. The approach is intended to give clinicians a more rounded, representative picture of a patient's sleep while making the testing experience more comfortable and accessible. The TIME Best Inventions Special Mention recognizes Wesper at a moment when sleep health is receiving increased attention as a critical component of overall health. The recognition reflects the larger shift toward technology that can move healthcare past traditional clinical settings and give people more convenient ways to understand their health. For Wesper, the recognition also reinforces its broader mission to modernize sleep testing and help more people identify conditions such as sleep apnea that can otherwise go undiagnosed. To learn more about Wesper, please visit wesper.co. For all media inquiries, please contact Madison Baptiste, publicist at Otter PR, via email at [email protected]. About Wesper Wesper is a home sleep testing ecosystem that delivers the right amount of diagnostic power for every patient. Wesper Lab provides high-fidelity respiratory data; Wesper Lite provides PPG-based diagnostics validated at 96% AHI correlation to PSG. One ecosystem, two diagnostic tiers - matched to the patient, not the inventory. Contact Info: Name: Madison Baptiste Email: Send Email Organization: Wesper Website: https://wesper.co/ Release ID: 89206289 If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify Ohsem.me (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Ohsem.me will respond and rectify the situation in the next 8 hours. 02/07/2026 18/08/2014 13/05/2026 27/04/2026 17/04/2026 Discover more Tech gadget reviews Agricultural Technology Consulting Farm Management Software Blog 16/10/2026

Citybiz
Jun 11th, 2026
Wesper launches Wesper Lite, diagnostic PPG device for general sleep testing.

Wesper launches Wesper Lite, diagnostic PPG device for general sleep testing. June 11, 2026 Wesper, a leader in advanced home sleep apnea testing (HSAT), today unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right patient without changing how their clinic works. Wesper will demo both products at booth #1007 at SLEEP 2026. As demand for sleep testing continues to outpace capacity, the Wesper ecosystem gives clinicians flexibility across the full range of patients they see. Wesper Lab is the company's high-fidelity, respiratory-based test, built for comprehensive analysis and ongoing follow-up with cannula-free airflow, positional analysis, and central apnea detection. Wesper Lite is an optical sensor-based (PPG) test designed for general diagnostics, high-volume screening, and remote patient monitoring. Both run on Wesper's robust signal analysis capabilities, and a Lite study can escalate to a Lab study without re-onboarding the patient. "Sleep apnea is a complicated condition that presents uniquely in every patient, but existing sleep testing has often been approached as one-size-fits-all," said Dr. Amir Reuveny, CEO and Founder of Wesper. "With Wesper Lab and Wesper Lite on one ecosystem, physicians can choose the right test for each patient and follow that patient through diagnosis, treatment, and ongoing monitoring on a single record. That is what personalized sleep testing - and ultimately personalized care, looks like." Wesper is also presenting three research posters at SLEEP 2026, including new data on provider-tuned autoscoring, AI-driven central sleep apnea detection validated against polysomnography, and an underrecognized positional OSA phenotype in obese patients. The studies reinforce the clinical depth behind the ecosystem and the value of direct, multi-night respiratory data. More on Wesper's Poster Presentations: * Provider-Specific Optimization Improves Agreement Between Automated and Provider-Scored AHI. Abstract ID: 1518 * Hypoxia-Dominant Positional OSA in Obese Patients: An Underrecognized Phenotype. Abstract ID: 1578 * Enhancing Central Sleep Apnea Detection via AI-Driven Autoscoring by a Wearable HSAT. Abstract ID: 567 About Wesper Wesper is a home sleep testing ecosystem that delivers the right amount of diagnostic power for every patient. Wesper Lab provides high-fidelity respiratory data; Wesper Lite provides PPG-based diagnostics validated at 96% AHI correlation to PSG. One ecosystem, two diagnostic tiers - matched to the patient, not the inventory.

PR Newswire
Jun 10th, 2026
Wesper unveils multi-tier sleep diagnostic ecosystem with dual testing pathways at SLEEP 2026

Wesper, a home sleep apnea testing company, has unveiled a multi-tier sleep diagnostic ecosystem at SLEEP 2026. The platform combines two diagnostic pathways — Wesper Lab and Wesper Lite — into one system with unified patient records and interpretation. Wesper Lab offers high-fidelity respiratory-based testing with cannula-free airflow, positional analysis and central apnea detection. Wesper Lite provides optical sensor-based testing for general diagnostics, screening and remote monitoring. Patients can escalate from Lite to Lab studies without re-onboarding. The company presented three research posters at the conference covering provider-tuned autoscoring, AI-driven central sleep apnea detection validated against polysomnography, and positional obstructive sleep apnoea phenotypes in obese patients. Wesper Lite demonstrates 96% apnoea-hypopnoea index correlation to polysomnography.

PR Newswire
May 15th, 2025
Wesper Is Rewriting Sleep Apnea Diagnosis: The Fda-Cleared Tech That Replaces Cannulas With Comfort

NEW YORK, May 15, 2025 /PRNewswire/ -- Studies show that up to 70% of sleep apnea cases may go undiagnosed when home sleep tests rely solely on indirect signals like oxygen desaturation or peripheral arterial tone, rather than directly measuring airflow [1]

PR Newswire
Feb 11th, 2025
Wesper Revolutionizes Glp-1 Sleep Apnea Screening And Enables Personalized Treatment

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Wesper, a leader in advanced home sleep apnea testing (HSAT), is transforming how obesity and sleep apnea are managed by integrating groundbreaking biometric sleep data with metabolic health innovations. Following the FDA approval of GLP-1 receptor agonists for sleep apnea treatment, Wesper is working with hospitals and physicians to bridge the gap between obesity, diabetes, GLP-1 medications, and sleep apnea

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Wesper right now.

Find jobs on Simplify and start your career today

We update Wesper's jobs every few hours, so check again soon! Browse all jobs